14.8  References

Arnaiz 2001  
Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. European Journal of Clinical Pharmacology 2001; 57: 89-91.

Asaria 2006  
Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it by 2010? BMJ 2006; 333: 890-895.

Chan 2004  
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-2465.

Derry 2001  
Derry S, Kong LY, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology 2001; 1: 7.

Edwards 1999  
Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management 1999; 18: 427-437.

Glasziou 2004  
Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004; 328: 39-41.

Glasziou 2007  
Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007; 334: 349-351.

Golder 2006  
Golder S, McIntosh HM, Duffy S, Glanville J, Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Information and Libraries Journal 2006; 23: 3-12.

Herxheimer 2002  
Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002, Issue 2. Art No: CD001520.

Ioannidis 2004  
Ioannidis JPA, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004; 141: 781-788.

Jick 1977  
Jick H. The discovery of drug-induced illness. New England Journal of Medicine 1977; 296: 481-485.

Jüni 2004  
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet 2004; 364: 2021-2029.

Kelly 2003  
Kelly WN. The quality of published adverse drug event reports. Annals of Pharmacotherapy 2003; 37: 1774-1778.

Koch-Weser 1977  
Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. European Journal of Clinical Pharmacology 1977; 11: 75-78.

Lanctot 1995  
Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clinical Pharmacology and Therapeutics 1995; 58: 692-698.

Loke 2004  
Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. British Journal of Clinical Pharmacology 2004; 57: 616-621.

Loke 2006  
Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions–systematic literature survey of follow-up. BMJ 2006; 332: 335-339.

McIntosh 2004  
McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Medical Research Methodology 2004; 4: 19.

Miettinen 1983  
Miettinen OS. The need for randomization in the study of intended effects. Statistics in Medicine 1983; 2: 267-271.

Olsen 1999  
Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Pressure 1999; 8: 94-101.

Papanikolaou 2006  
Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. Canadian Medical Association Journal 2006; 174: 635-641.

Schulz 2002  
Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. The Lancet 2002; 359: 696-700.

Stricker 2004  
Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-47.

Vandenbroucke 2004  
Vandenbroucke JP. When are observational studies as credible as randomised trials? The Lancet 2004; 363: 1728-1731.

Vandenbroucke 2006  
Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? Canadian Medical Association Journal 2006; 174: 645-646.

Venning 1982  
Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. British Medical Journal (Clinical Research Edition) 1982; 284: 249-252.

Venning 1983  
Venning GR. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? British Medical Journal (Clinical Research Edition) 1983; 286: 365-368.